Pediatric cancer is an urgent and important problem that requires highly precise diagnostics and therapeutic approaches, however many of the necessary tools have yet to be developed.
Around 60% of pediatric cancers are solid tumors, and the prognosis of these cancers is poor with mortality as high as 40%. Despite current therapies such as chemotherapy and radiation, relapse may still occur with mortality up to 66%.
Advanced solid tumors are highly complex and extremely successful at evading the immune response. They are characterized by aberrant cell proliferation and vascularization, resulting in a hypoxic environment inhospitable to most cells, as well as containing their own immunosuppressive immune cells.
Dr. David Steffin, a pediatric oncologist and assistant professor at Texas Children’s Hospital/Baylor College of Medicine, Houston, joined us for a webinar to discuss how he and his team have implemented CODEX® to aid his efforts in developing novel treatments for children with solid tumors.